4-[4-(5-benzylpyrimidin-2-yl)piperazin-1-yl]-N-[3-[(dimethylamino)methyl]phenyl]-1,3,5-triazin-2-amine
C27H31N9 — CID 118031494
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[4-(5-benzylpyrimidin-2-yl)piperazin-1-yl]-N-[3-[(dimethylamino)methyl]phenyl]-1,3,5-triazin-2-amine
4-[4-(5-benzylpyrimidin-2-yl)piperazin-1-yl]-N-[3-[(dimethylamino)methyl]phenyl]-1,3,5-triazin-2-amine (PubChem CID 118031494) has the molecular formula C27H31N9 and a molecular weight of 481.61 g/mol. Its IUPAC name is 4-[4-(5-benzylpyrimidin-2-yl)piperazin-1-yl]-N-[3-[(dimethylamino)methyl]phenyl]-1,3,5-triazin-2-amine.
Molecular Properties
| Compound Name | 4-[4-(5-benzylpyrimidin-2-yl)piperazin-1-yl]-N-[3-[(dimethylamino)methyl]phenyl]-1,3,5-triazin-2-amine |
|---|---|
| PubChem CID | 118031494 |
| Molecular Formula | C27H31N9 |
| Molecular Weight | 481.61 g/mol |
| Exact Mass | 481.27 |
| IUPAC Name | 4-[4-(5-benzylpyrimidin-2-yl)piperazin-1-yl]-N-[3-[(dimethylamino)methyl]phenyl]-1,3,5-triazin-2-amine |
| SMILES | CN(C)Cc1cccc(Nc2ncnc(N3CCN(c4ncc(Cc5ccccc5)cn4)CC3)n2)c1 |
| InChI | InChI=1S/C27H31N9/c1-34(2)19-22-9-6-10-24(16-22)32-25-30-20-31-27(33-25)36-13-11-35(12-14-36)26-28-17-23(18-29-26)15-21-7-4-3-5-8-21/h3-10,16-18,20H,11-15,19H2,1-2H3,(H,30,31,32,33) |
| InChIKey | IUDDGSMHXPLJIA-UHFFFAOYSA-N |
| XLogP | 3.38 |
| TPSA | 86.20 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 481.61 |
| LogP ≤ 5 | 3.38 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118031494 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.